Dupilumab Compassionate Use Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03020810|
Expanded Access Status : Approved for marketing
First Posted : January 13, 2017
Last Update Posted : March 7, 2018
|Condition or disease||Intervention/treatment|
This study is being undertaken to determine whether dupilumab has efficacy in extremely severe asthma, and to allow a very severe asthma patient, who has been tried on nearly every immunosuppressive drug, early access to a potentially effective therapy.
The patient will continue in the study indefinitely. Safety will be evaluated and serious adverse events will be reported.
|Study Type :||Expanded Access|
|Official Title:||Dupilumab Compassionate Use Study|
- Drug: Dupilumab
The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks